AI Summary

In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, and produced a median duration of response of 11.2 months before the cancer progressed.

AI summaries can be wrong sometimes—always verify important details using the source article.